NYSE · ZTS
Healthcare · Drug Manufacturers - Specialty & Generic
$74.81
Up+$1.69 (+2.31%)
Updated Oct 10, 2026, 5:31 PM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · ZTS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
ZTS closed at $74.81 after 21 trading sessions, up 2.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $73.04 | $74.85 | $73.00 | $74.81 | 2.91M |
| Oct 8, 2026 | $71.36 | $73.75 | $71.15 | $73.08 | 6.18M |
| Oct 7, 2026 | $71.73 | $72.09 | $71.115 | $71.55 | 4.13M |
| Oct 6, 2026 | $71.88 | $72.30 | $70.59 | $71.33 | 3.44M |
| Oct 5, 2026 | $69.41 | $71.47 | $69.00 | $71.41 | 3.64M |
| Oct 2, 2026 | $69.12 | $70.10 | $68.77 | $69.69 | 5.26M |
| Oct 1, 2026 | $70.00 | $70.90 | $68.92 | $69.10 | 5.35M |
| Sep 30, 2026 | $70.55 | $70.765 | $69.52 | $69.83 | 4.44M |
| Sep 29, 2026 | $71.40 | $71.70 | $69.995 | $70.30 | 3.52M |
| Sep 28, 2026 | $70.50 | $71.6762 | $70.08 | $71.43 | 3.91M |
| Sep 25, 2026 | $70.00 | $71.08 | $69.52 | $71.05 | 4.17M |
| Sep 24, 2026 | $71.85 | $72.38 | $69.93 | $70.27 | 3.37M |
| Sep 23, 2026 | $72.75 | $73.55 | $71.55 | $71.61 | 3.83M |
| Sep 22, 2026 | $71.98 | $73.46 | $71.24 | $72.86 | 3.84M |
| Sep 21, 2026 | $72.06 | $72.475 | $70.26 | $71.33 | 3.95M |
| Sep 18, 2026 | $72.565 | $73.05 | $71.40 | $71.40 | 9.88M |
| Sep 17, 2026 | $73.35 | $73.445 | $72.00 | $73.02 | 4.04M |
| Sep 16, 2026 | $73.47 | $73.90 | $72.92 | $73.00 | 4.59M |
| Sep 15, 2026 | $72.91 | $73.7825 | $72.72 | $73.43 | 4.08M |
| Sep 14, 2026 | $74.20 | $74.82 | $73.485 | $73.67 | 3.77M |
| Sep 11, 2026 | $73.24 | $73.50 | $71.50 | $72.97 | 5.24M |
The latest Smart Investors Daily articles mentioning ZTS.
Company
Market Activity
Research & News
ZTS research
Company profile and research snapshot.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 20, 2026 | Stifel | Hold | — |
| Aug 11, 2026 | Citigroup | Buy | — |
| Aug 11, 2026 | BNP Paribas | Outperform | — |
| Aug 10, 2026 | Piper Sandler | Neutral | — |
No generated briefing is available yet.
Yahoo · Oct 2, 2026
Zoetis Inc. (NYSE:ZTS) has built one of the strongest franchises in animal health. Its products are used by veterinarians around the world; its portfolio spans medicines, vaccines, and diagnostics, and its research capabilities have helped establish entire categories of treatment. But a moat is only valuable if it protects market share and pricing power when […]
Yahoo · Oct 1, 2026
Zoetis (ZTS) reached $69.1 at the closing of the latest trading day, reflecting a -1.05% change compared to its last close.
SeekingAlpha · Sep 30, 2026
Zoetis (ZTS) stock: why shares fell 71% and whatâs next. Margin strength, pipeline vs. 2030+ patent risks, and $113 fair value.
ChartMill · Sep 25, 2026
Zoetis (ZTS) screens as decent value: low P/E, strong 9/10 profitability, solid ROIC, and a sustainable dividend, though growth and leverage are risks.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ZTS.
